In agreement with this role, the D2R agonist bromocriptine was shown to improve glycemic control and glucose tolerance in obese type 2 diabetic patients, being approved by the FDA for the treatment of type 2 diabetes. This evidence concerns the gene DRD2 and type 2 diabetes mellitus.